Of note, a recent clinical trial provided evidence that infusion of ex vivo CCR5-edited CD4+ T cells could delay viral rebound and that post-rebound control of infection was possible in 1 of 9 CCR5wt/wt PLWH [249]. The gene discussed is CCR5; the disease is infection.